Insider · CIK 0002028936
Jane Ryan
Files at NEUP (Neuphoria Therapeutics Inc.). First filing -, latest -.
Jane Ryan files SEC Form 4 as director at NEUP (Neuphoria Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jane Ryan has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | NEUP Neuphoria Therapeutics Inc. | AGrant or award Restricted Stock Unitsderivative | +8,537 | $0.00 | $0 | 15,550 | Jan 21, 2026 |
| Apr 16, 2025 | NEUP Neuphoria Therapeutics Inc. | AGrant or award Restricted Stock Unitsderivative | +6,783 | $0.00 | $0 | 7,013 | Apr 18, 2025 |
Questions about Jane Ryan
Answered from the filings on this page, as of the latest one.
Is Jane Ryan buying or selling?
Jane Ryan has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jane Ryan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jane Ryan has 0.
Where does Jane Ryan file Form 4?
Jane Ryan has filed Form 4 at NEUP (Neuphoria Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.